IL17A and psoriatic arthritis: Consensus was reached on the following eligibility criteria: a minimal treatment duration of and minimal low disease activity for 6 months; PASI ≤5 and/or PGA 0-2 and DLQI ≤5 at the start of DR; a rheumatologist needs to be consulted prior to DR in the case of psoriatic arthritis; outpatient clinic visits should not become more frequent when DR is applied; and DR (of IL-17 and IL-23 inhibitors) can be considered in individual patients while awaiting more scientific evidence.